Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC, commonly known as Hikma, is a leading global pharmaceutical company headquartered in the United Kingdom. Founded in 1978, Hikma has established a strong presence in key operational regions, including the Middle East, North Africa, and the United States. The company operates primarily in the generic and branded pharmaceuticals sectors, focusing on injectable medications, oral solids, and complex generics. Hikma is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic areas, including oncology, pain management, and infectious diseases. With a robust market position, Hikma has achieved significant milestones, including numerous FDA approvals and a growing pipeline of new therapies. The company's dedication to improving patient outcomes and expanding access to essential medicines underscores its reputation as a trusted leader in the pharmaceutical industry.
DitchCarbon Score
How does Hikma Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikma Pharmaceuticals's score of 53 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hikma Pharmaceuticals's reported carbon emissions
In 2023, Hikma Pharmaceuticals reported total carbon emissions of approximately 43830000 kg CO2e for Scope 1 and about 79897000 kg CO2e for Scope 2, resulting in a combined total of around 123727000 kg CO2e for these two scopes. The company has not disclosed any Scope 3 emissions data for this year, which is significant as Scope 3 often represents the majority of a company's carbon footprint. Hikma's emissions have shown fluctuations over the years. For instance, in 2022, the company reported approximately 42346000 kg CO2e for Scope 1 and about 78140000 kg CO2e for Scope 2, leading to a total of around 120486000 kg CO2e. This indicates a slight increase in emissions in 2023 compared to 2022. Despite the lack of specific reduction targets or initiatives disclosed, Hikma Pharmaceuticals is actively monitoring its emissions and has committed to transparency in its reporting. The company has not set any Science-Based Targets Initiative (SBTi) reduction targets, which are crucial for aligning corporate emissions with climate science. Overall, while Hikma Pharmaceuticals has made strides in emissions reporting, the absence of defined reduction targets highlights an area for potential improvement in their climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 49,779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hikma Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
